Background-Atrial fibrillation represents the most common arrhythmia leading to increased morbidity and mortality, yet, current treatment strategies have proven inadequate. Conventional treatment with antiarrhythmic drugs carries a high risk for proarrhythmias. The soluble epoxide hydrolase enzyme catalyzes the hydrolysis of anti-inflammatory epoxy fatty acids, including epoxyeicosatrienoic acids from arachidonic acid to the corresponding proinflammatory diols. Therefore, the goal of the study is to directly test the hypotheses that inhibition of the soluble epoxide hydrolase enzyme can result in an increase in the levels of epoxyeicosatrienoic acids, leading to the attenuation of atrial structural and electric remodeling and the prevention of atrial fibrillation. Methods and Results-For the first time, we report findings that inhibition of soluble epoxide hydrolase reduces inflammation, oxidative stress, atrial structural, and electric remodeling. Treatment with soluble epoxide hydrolase inhibitor significantly reduces the activation of key inflammatory signaling molecules, including the transcription factor nuclear factor κ-lightchain-enhancer, mitogen-activated protein kinase, and transforming growth factor-β. Conclusions-This study provides insights into the underlying molecular mechanisms leading to atrial fibrillation by inflammation and represents a paradigm shift from conventional antiarrhythmic drugs, which block downstream events to a novel upstream therapeutic target by counteracting the inflammatory processes in atrial fibrillation.
A trial fibrillation (AF) represents one of the most common arrhythmias seen clinically and is associated with a significant increase in morbidity and mortality, 1 yet, current treatment paradigms have proven largely inadequate. 2 Treatment with conventional antiarrhythmic drugs generally carries a high risk of proarrhythmia. 3 Moreover, prevalence of AF is increasing because of the aging population.
There is a strong evidence supporting the involvement of inflammation in the pathophysiology of AF. 1, 4, 5 Inflammatory infiltrates and increased serum levels of proinflammatory cytokines have been demonstrated in animal models and patients with AF. [6] [7] [8] In addition, inflammation has been implicated in diseases that predispose patients to AF and AF-related processes including oxidative stress and fibrosis. 5, 7 Structural and electric remodeling represent the main pathophysiological mechanisms contributing to the initiation and maintenance of AF. Moreover, AF can exacerbate inflammation that further perpetuates the arrhythmia. Hence, reduction of inflammation and reversal of structural remodeling have increasingly become the focus of new therapeutic strategies for the treatment of AF.
One of the most robust inflammatory responses is the activation of phospholipase A 2 and the release of arachidonic acid, which is metabolized through the cyclooxygenase, lipoxygenase, and cytochrome P450 pathways. The cytochrome P450 epoxidized products, the epoxyeicosatrienoic acids have been shown to have anti-inflammatory and profibrinolytic with several cardioprotective effects. 9 However, epoxyeicosatrienoic acids are further metabolized by the soluble epoxide hydrolase (sEH) enzyme to form the corresponding 1,2-diols, dihydroxyeicosatrienoic acids with diminished antiinflammatory activities. 9 Indeed, the cardioprotective activity of epoxyeicosatrienoic acids can be enhanced by blocking the degradation of epoxyeicosatrienoic acids to corresponding dihydroxyeicosatrienoic acids using potent inhibitors of sEH (sEHI). 10 We have previously demonstrated the beneficial effects of sEHIs in clinically relevant models of cardiac hypertrophy and failure. [11] [12] [13] [14] We further demonstrate that treatment with sEHIs reduces atrial arrhythmia inducibility in cardiac hypertrophy models. 12 However, the molecular mechanisms underlying the prevention of atrial arrhythmia inducibility by sEHIs remain unexplored.
Hence, in this study, we sought to directly test the molecular mechanisms in the prevention of AF using an in vivo pressure-overload model to replicate chronic hypertension, a major risk factor for AF. We further use an in vitro model of human-induced pluripotent stem cell (hiPSC)derived atrial myocytes and fibroblasts to test the hypotheses that inhibition of sEH attenuates AF by reducing (1) inflammation, (2) atrial structural remodeling, and (3) electric remodeling in atrial myocytes. Our study not only provides important mechanistic insights into the roles of inflammation and atrial fibrosis in AF but also represents a proof-of-concept study for a novel therapeutic target for the treatment of AF.
Methods
The animal study was performed in accordance with the approved UC Davis Animal Care and Use protocol. Additional experimental details can be found in the Methods in the Data Supplement.
Thoracic Aortic Constriction Model in Mice
Thoracic aortic constrictions (TACs) were performed in 8-to 12-week-old male C57BL/6J mice as previously described. 13 One week after surgery, mice were randomized in an investigator-blinded manner to receive either vehicle alone or 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea (TPPU; Figure 1A ) for 3 weeks ( Figure 1B ). 13
Analysis of Cardiac Function by Echocardiography
Echocardiograms were performed as described previously. 12 Fractional shortening was calculated from left ventricle dimensions as follows: % fractional shortening=([end diastolic dimension−end systolic dimension]/end diastolic dimension)×100.
Histological Analyses
Excised hearts were retrogradely perfused with phosphate-buffered solution to wash out blood. Fixed hearts were embedded in paraffin, and serial left atrial (LA) and right atrial (RA) sections of 5 μm in thickness were taken along the longitudinal axis and stained with Picrosirius Red to assess for collagen content.
Immunofluorescence Confocal Laser Scanning Microscopy
Additional cardiac sections were stained with wheat germ agglutinin. Deparaffinized sections were rehydrated with serial dilution of ethanol, serum blocked, and stained. Sections from corresponding area from the 4 groups were scanned.
Flow Cytometric and Electrophysiological Studies of Single Isolated Cardiac Cells
Single cells were obtained using enzymatic digestion. LA and RA myocytes were used for electrophysiological studies using conventional whole-cell patch-clamp technique at room temperature. 12 Currents were recorded using Axopatch 200B amplifier, filtered at 10 kHz, and digitized at sampling frequency of 50 kHz.
For flow cytometric analysis, fixed cells were permeabilized, stained with anti-Thy1.2, lineage, anti-CD45, anti-troponin T, anti-CD31, anti-phosphorylated extracellular signal-regulated kinase 1 and 2 (pERK1/2), anti-phosphorylated Smad2/3 (pSMAD2/3), Ki67 antibodies, and 7-aminoactinomycin D. Data were collected using FACScan cytometer and analyzed using FlowJo software. Cells stained with isotype-matched IgG antibodies were used as controls to determine the positive cell population.
Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
HiPSCs were plated and differentiated for 20 days using a directed differentiation protocol. 15 HiPSC-cardiomyocytes (CMs) enriched with puromycin and treated with tumor necrosis factor-α (TNF-α) or angiotensin II (ANG II) and TPPU were fixed and stained with anti-α-actinin, anti-nuclear factor κ-light-chain-enhancer (NF-κB), anti-myosin light chain-2a (MLC2a), anti-MLC-2v (MLC2v), and fibroblast-specific antibodies.
In Vitro Human Cardiac Fibroblast Culture
Human RA appendage specimens from informed consented patients undergoing cardiac bypass surgery were obtained from UC Davis Medical Center in accordance with the approved UC Davis Institutional Review Board protocol. Partially digested cardiac tissues were plated on cell culture dishes until the appearance of fibroblasts from the explants. Trypsinized cells were replated, treated with ANG II and TPPU and stained with anti-Thy1.1, lineage, anti-CD45, and Ki67 antibodies for flow cytometry.
WHAT IS KNOWN
• Atrial fibrillation (AF) represents the most common arrhythmia leading to increased morbidity and mortality, yet, current treatment strategies have proven inadequate.
• The soluble epoxide hydrolase enzyme (sEH) catalyzes the hydrolysis of anti-inflammatory epoxy fatty acids including epoxyeicosatrienoic acids from arachidonic acid to the corresponding diols.
WHAT THE STUDY ADDS
• Inhibition of sEH reduces inflammation, oxidative stress, fibrosis, and electrical remodeling. Mechanistically, treatment with sEH inhibitor significantly reduces the activation of key inflammatory signaling molecules, including the transcription factor nuclear factor κ-light-chain-enhancer (NF-κB), mitogen-activated protein kinase (MAPK) and transforming growth factor-β (TGF-β).
• This study provides insights into the underlying molecular mechanisms leading to AF by inflammation and represents a paradigm shift from conventional antiarrhythmic drugs which block downstream events to a novel upstream therapeutic target by counteracting the inflammatory processes in AF. New Treatment Paradigm for Atrial Fibrillation
Western Blot Analysis
Immunoblots were performed as previously described 16 using anti-IκB, antiphospho-IκB, anti-NF-κB, and anti-GAPDH antibodies.
Measurement of Plasma Cytokine Levels
Plasma cytokine levels from samples collected 3 weeks after sham or TAC operations were analyzed using a Cytometric Bead Array kit and Cytometric Bead Array Analysis software following the manufacturer's protocol. 13 
Evaluation of Endoplasmic Reticulum Stress markers
Total protein isolated from atrial tissues homogenized in radio-immunoprecipitation assay (RIPA) buffer supplemented with protease and phosphatase inhibitors were resolved by SDS-PAGE, and immunoblotting was performed using antibodies for pp38 (Thr180/ Tyr182), p38, pJNK (Thr183/Tyr185), c-Jun N-terminal kinases (JNK), pPERK (Thr980), PERK, peIF2α (Ser51), eukaryotic translation initiation factor 2 (eIF2α), sXBP1, inositol requiring enzyme 1α (IRE1α), pIRE1α (Ser724), and tubulin. Proteins were visualized using enhanced chemiluminescence and quantified using ImageQuant 5.0 software. Data for phosphorylated proteins are presented as phosphorylation level normalized to total protein expression and for nonphosphorylated proteins as total protein expression normalized to β-tubulin.
Ex Vivo Optical Mapping of Transmembrane Potential (V m )
Hearts from heparin-injected anesthetized mice were perfused in Tyrode solution with the posterior surface of the heart facing the optical mapping camera using Langendorff apparatus. 17 A bipolar pacing electrode was positioned on the epicardium of LA or RA appendage for pacing using a 2 ms pulse at twice the diastolic threshold. The heart was stained with the voltage-sensitive dye (RH237) via the coronary perfusion. Optical action potentials were recorded using a 16-bit complementary metal oxide camera and images acquired at 1 kHz.
Statistical Analysis
Statistical comparisons were analyzed by 1-way ANOVA followed by Bonferroni tests and Tukey-Kramer honest significant difference analyses for post hoc comparison.
Results

Prevention of Atrial Myocyte Hypertrophy With sEHI in a Murine TAC Model
TPPU has been shown previously to have high inhibitory potency, long enzyme dissociation half-life, pharmacokinetic half-life with drug-like properties, and a comparable elevation of epoxyeicosatrienoic acids concentration in plasma as the sEH knockout mice (EPHX2 −/− ). 13, 18 TAC mice exhibited cardiac hypertrophy, a significant increase in heart weight/body weight ratio (HW/BW; Figure 1C We analyzed the forward light scattering by flow cytometry as an index of atrial myocyte size using isolated single atrial cells. Atrial myocytes were gated based on the presence of cardiac-specific troponin T. There was a significant increase in atrial myocyte size in TAC-operated group ( Figure 1E and 1F) compared with sham-operated groups. More importantly, atrial myocyte hypertrophy was reduced in animals treated with TPPU ( Figure 1F ). We further confirmed the findings using patch-clamp recordings and cell capacitance measurement showing a significant increase in myocyte size in TAC-operated mice (118±4 pF) compared with sham, shamoperated, and TAC-TPPU treated groups (64±10, 67±7, and 71±2 pF, respectively). Finally, the myocyte size from LA and RA was directly compared using a Coulter multisizer assay to quantify the cell volume. 13 The myocyte volume significantly increased in both LA and RA from TAC mice, which was restored to the sham-operated control levels by the TPPU treatment ( Figure 1G ). Interestingly, the myocyte volume was significantly smaller for RA compared with LA in all 3 groups (sham, TAC, and TAC-treated; P<0.05).
The effect of TPPU on the chamber size and systolic function was assessed using echocardiography. There was a significant decrease in left ventricular end-diastolic dimension ( Figure II in the Data Supplement) associated with a significant improvement in fractional shortening ( Figure 1H ) post TPPU treatment. In contrast, left ventricular end-diastolic dimension in TAC mice increased from week 1 to week 4 suggesting adverse remodeling.
Target Engagement of TPPU in Mouse TAC Model
To demonstrate the inhibition of sEH by TPPU, metabolic profiling of arachidonic acid metabolites of the cytochrome P450 pathway was performed after 3 weeks of treatment as previously described. 13 There was a significant increase in the epoxyeicosatrienoic acids/dihydroxyeicosatrienoic acids ratio in the TPPU-treated groups compared with TAC alone group ( Figure 1I ; Table I in the Data Supplement). Moreover, analysis of arachidonic acid metabolites of the cyclooxygenase pathway demonstrates an increase in proinflammatory thromboxane and prostaglandin levels in the TAC model, which was attenuated with TPPU treatment ( Figure IIIA and Table II in the Data Supplement). Metabolites of the lipoxygenase pathways demonstrated a modest difference between the 4 groups ( Figure IIIB and Table II in the Data Supplement).
Treatment With TPPU Results in a Significant Reduction in Inflammatory Cytokines and Chemokine
Although the precise underlying mechanisms for atrial fibrosis in AF have not been fully elucidated, a network of profibrotic factors including proinflammatory cytokines is known to contribute toward AF in the clinical setting. 19 Our data demonstrate a significant increase in proinflammatory cytokine and chemokine levels including interferon-γ, TNF-α, and monocyte chemoattractant protein-1 in the TAC mice ( Figure 1J and 1K). Importantly, treatment with TPPU significantly decreased the cytokine and chemokine levels.
Treatment With TPPU Significantly Reduces Atrial Fibrosis and Atrial Fibroblast Activation
Previous studies have provided a strong link between atrial fibrosis and atrial structural remodeling in the development of AF 1, 4 ; however, the precise mechanisms for atrial fibrosis remain incompletely understood. The secretory, migratory, and proliferative capacity of cardiac fibroblasts increases after injury. 13 Proinflammatory cytokines and profibrotic factors, such as ANG II, induce cardiac fibrosis by activating cardiac fibroblasts resulting in an increase in collagen synthesis. 1 However, there are regional differences in structural remodeling between atria and ventricles with atria being particularly prone to fibrosis. 20 Indeed, atrial fibroblasts are distinct from ventricular fibroblasts in their morphology, gene expression, secretory, and proliferative patterns. 21 Here, we demonstrate the presence of atrial fibrosis in LA (Figure 2A and 2B) and RA ( Figure IV in the Data Supplement) sections using Picrosirius Red stain and wheat germ agglutinin that binds to highly glycosylated collagen protein in TAC hearts. However, there was a marked decrease in collagen deposition in the TPPU-treated atrial tissue sections compared with the TAC alone. Next, we analyzed atrial fibroblasts isolated from sham, sham-treated, TAC, and TAC-treated hearts. Atrial fibroblasts were defined as Thy1.2 + / Lin − /CD31 − /CD45 − cells (Mouse-Thy pos cells) using flow cytometry. 13 There was a significant increase in percentages of Thy pos cells in the atria of TAC compared with the 2 groups of sham animals ( Figure 2C and 2D) . Treatment with TPPU resulted in a significant decrease in percentages of Thy pos cells compared with TAC animals.
In Vitro Models of Human Atrial Fibroblasts and hiPSC-Derived Cardiac Fibroblasts
The effects of TPPU observed in the atria may be secondary to the reduction in ventricular hypertrophy and adverse remodeling in the ventricles. Therefore, to directly demonstrate the effects of sEH inhibition specifically on atrial fibroblasts and independent of ventricular influence, we used atrial fibroblasts isolated from human atrial appendages as well as an in vitro model of hiPSC-derived cardiac fibroblasts (hiPSC-fibroblasts).
Human atrial fibroblasts were isolated and quantified as cells expressing Thy1.1 + /Lin − /CD45 − (Human-Thy pos cells) using flow cytometry ( Figure 2E ). There was a significant increase in percentages of human atrial fibroblasts in the ANG II-treated group compared with the control ( Figure  2F ), and treatment with TPPU resulted in a decrease in percentages of human Thy pos cells. We further used Ki67 to analyze the proliferative capacity among human atrial fibroblasts stimulated with ANG II. There was a significant increase in the percentage of Ki67 in the ANG II-treated human atrial fibroblasts compared with control ( Figure 2G and 2H). Treatment with TPPU in the ANG II-stimulated cells resulted in a significant decrease in Ki67 expression in human atria fibroblasts.
HiPSC-fibroblasts were defined as Thy1.1 + /Lin − /CD45 − cells (hiPSC-Thy pos cells). ANG II treatment significantly increased the percentages (Figure 2I and 2J) and proliferative capacity ( Figure 2K and 2L) of hiPSC-fibroblasts compared with the control. Treatment with TPPU in the ANG IIstimulated cells resulted in a significant decrease in the percentages and Ki67 positivity in the hiPSC-fibroblasts.
Treatment With TPPU Results in a Significant Reduction in the Activation of Mitogen-Activated Protein Kinase and Transforming Growth Factor-β Signaling Cascades in Atrial Fibroblasts and Myocytes
Inflammatory cytokines and chemokines including interferon-γ, TNF-α, and monocyte chemoattractant protein-1 have been shown to contribute to cardiac fibrosis by activating cardiac fibroblasts via the mitogen-activated protein kinase (MAPK) signaling cascade. 13 Indeed, increased circulatory levels of TNF-α have been demonstrated in patients with heart failure. 22 The Smad signaling cascade regulated by transforming growth factor-β (TGF-β) also contributes to cardiac fibrosis. 23 Upregulated TGF-β in cardiac fibroblasts activates Smad transcription factors, which translocate to the nucleus to activate the promoters of collagen I and III genes. 24, 25 Moreover, cardiac hypertrophy is also stimulated by the interplay of MAPK and TGF-β. 25, 26 To elucidate the effects of TPPU on the MAPK and TGF-β signaling cascades, we examined the activation of downstream members, the ERK1/2 and Smad2/3 in atrial fibroblasts and myocytes. Our data demonstrate a significant elevation in the levels of phosphorylated ERK1/2 (pERK1/2) in atrial fibroblasts ( Figure 3A and 3B) and myocytes ( Figure 3C and 3D) in the TAC mice that was significantly decreased in TPPU-treated TAC mice. Similarly, there was a significant elevation in the levels of pSmad2/3 in atrial fibroblasts (Figure 3E and 3F) and myocytes ( Figure 3G and 3H) in the TAC mice that was significantly decreased in TPPU-treated TAC mice. Taken together, our data suggest that TPPU decreases the production of cytokines and chemokines resulting in the decrease in the activation of atrial fibroblasts and myocyte hypertrophy, the leading contributors of adverse atrial structural remodeling associated with AF.
Treatment With TPPU Results in a Significant Reduction in Oxidative Stress in Atrial Fibroblasts and Myocytes
Systemic and myocardial-specific oxidative stress has been implicated in the pathogenesis of AF. 27 Elevated systemic levels of reactive oxygen species (ROS) are seen with increasing age, heart failure, and coronary heart disease, which are known risk factors for AF. 28 Here, flow cytometry was used to quantify the level of oxidative stress in atrial fibroblasts ( Figure 3I and 3J) and atrial myocytes ( Figure 3K and 3L ). There was a significant increase in ROS levels in atrial fibroblasts and atrial myocytes isolated from TAC compared with the 2 groups of sham animals. Moreover, treatment with TPPU resulted in a significant decrease in the ROS activity compared with TAC alone.
Direct Effects of TPPU in an In Vitro Model of hiPSC-Derived Atrial Myocytes and Fibroblasts Activated by Inflammatory Cytokine TNF-α
As mentioned above, the effects of sEHI in the prevention of atrial remodeling may be secondary to the reduction in ventricular hypertrophy. Therefore, to specifically elucidate the effects of inflammatory cytokines and the direct inhibitory effects of TPPU on atria, we used an in vitro model of hiPSC-derived atrial myocytes (hiPSC-ACMs) and hiPSC-fibroblasts. HiPSC-ACMs were selected based on the expression of MLC2a and the absence of MLC2v ( Figure 4A and 4B) . 29 Differentiated-hiPSCs were treated with TNF-α. Analysis of hiPSC-ACMs (MLC2a + / MLC2v − ) and hiPSC-fibroblasts stimulated with TNF-α demonstrated a significant increase in pERK1/2 compared with the control and control-TPPU-treated cells ( Figure 4C through  4E) . Moreover, treatment of TNF-α stimulated hiPSC-ACMs and hiPSC-fibroblasts with TPPU significantly decreased the pERK1/2 level. The presence of the sEH enzyme in hiPSCs was analyzed by flow cytometry (Figure 4F ). 
Treatment With TPPU Results in a Significant Reduction in the Activation of the NF-κB
NF-κB represents one of the critical players in the cytokinemediated inflammation and is associated with cardiac fibrosis, hypertrophy, and heart failure. 9 NF-κB is maintained in the inactive form when bound to IκB. Degradation of IκB by IκB kinase leads to the nuclear translocation of NF-κB and gene activation. Epoxyeicosatrienoic acids have been shown to regulate the NF-κB cascade by inhibiting IκB kinase. 9 Our data demonstrated an increased nuclear translocation of NF-κB Figure 5A ) and a significant increase in the pIκBα and nuclear NF-κB (nNF-κB) on TNF-α stimulation, which was significantly attenuated with TPPU treatment (Figure 5B through 5D ).
Treatment With TPPU Results in a Significant Reduction in Endoplasmic Reticulum Stress
Increasing evidence suggests that endoplasmic reticulum (ER) stress contributes to cardiac hypertrophy, fibrosis, and apoptosis. 30, 31 Perturbations in the ER homeostasis because of intrinsic and extrinsic factors, such as inflammation, oxidative stress, and ischemia may culminate in ER stress. This includes the activation of ER transmembrane protein sensors (PKR-like ER-regulated kinase [PERK] and inositol requiring enzyme 1α [IRE1α]), the upregulation of ER chaperones, such as binding of immunoglobulin protein, initiation of ERrelated apoptotic proteins, such as CCAAT/enhancer-binding protein homologous protein, and activation of MAPKs. [32] [33] [34] Chronic pressure overload in TAC animals resulted in the activation of PERK and IRE1α, and their downstream targets α-subunit of eIF2α and X-box binding protein 1 (XBP1), respectively in atrial tissues ( Figure VA 
Treatment With TPPU Reduces Atrial Electric Remodeling
Finally, optical mapping of transmembrane potential (V m ) was performed on isolated atria to determine the effects of TPPU on atrial electric remodeling. 36 There was an increase in action potential duration (APD; Figure 6A through 6D) in the atria isolated from TAC compared with TPPU-treated TAC animals. Atria from TAC hearts demonstrated a significant increase in APD at 80% of repolarization (APD 80 ) and APD dispersion (differences between LA and RA APD) compared with the TPPU-treated atria. Furthermore, atria isolated from TAC mice showed significantly longer effective refractory period in the LA versus RA ( Figure 6E) , indicating increased dispersion of repolarization and refractoriness in untreated hearts.
Consistent with the ex vivo findings, patch-clamp recordings from single isolated atrial myocytes demonstrated a significant downregulation of the transient outward K + current in TAC animals compared with sham or sham-treated animals. (Figure 6F and 6G ).
Discussion
Chronic hypertension represents one of most common comorbidities leading to AF. 37 The main pathophysiological mechanisms contributing to the initiation, progression, and persistence of AF are structural and electric remodeling of the atria. 37 Moreover, AF increases inflammation in the heart contributing to atrial remodeling substantiating the AF begets AF phenomenon. 7 In this study, we provide a proof-of-concept and the molecular mechanisms underlying the beneficial effects of inhibition of sEH in the treatment of AF. We demonstrate positive effects of sEHI in a pressure-overload-induced atrial remodeling model by reducing (1) inflammation, (2) atrial fibrosis, and (3) electric remodeling in atrial myocytes. Specifically, this study provides evidence to support the role of inhibition of sEH as a potent anti-inflammatory mechanism leading to a significant decrease in the systemic levels of cytokines and chemokines as well as the inhibition of NF-κB activation. Moreover, treatment with sEHI results in significant attenuation in the phosphorylation of key signaling molecules, including ERK1/2 in the MAPK pathway in atrial myocytes and atrial fibroblasts. To further demonstrate direct inhibitory effects of sEHI on atrial myocytes and atrial fibroblasts, we took advantage of in vitro models of hiPSC-ACMs and hiPSC-fibroblasts as well as human atrial fibroblasts isolated from atrial appendages. Taken together, our data provide compelling molecular and cellular evidence for the use of sEHI as an anti-inflammatory therapy for AF ( Figure 6H ).
Roles of Inflammation in AF
Inflammation has been shown to play critical roles in the pathophysiology of AF. 8 Evidence of inflammatory infiltrates and increased serum levels of proinflammatory cytokines were present in both animal models and patients with AF. [6] [7] [8] Several important molecular mediators in inflammatory responses in AF include the stretch-activated production of ANG II and the recruitment of inflammatory cells that secrete inflammatory cytokines and chemokines that activate one of the critical transcription factor, NF-κB. Activated NF-κB not only increases the gene expression of inflammatory cytokines, intensifying inflammation, it also leads to electric remodeling and myocytes hypertrophy. Hence, inflammatory cytokines act via a positive feedback mechanism further exacerbating AF ( Figure 6H ).
Inflammatory cytokines such as TNF-α and interferon-γ also disrupt protein folding in the ER. The ER is a multifunctional organelle playing an important role in protein-folding, calcium homeostasis, and in particularly in the heart it also contributes to the regulation of excitation-contraction coupling. 32, 34 When the folding capacity of ER is exceeded, misfolded proteins accumulate triggering ER stress. To mitigate ER stress and to restore ER homeostasis, the unfolded protein response is initiated. However, if unfolded protein response mechanisms are unable to lessen ER stress, cardiomyocyte apoptosis occurs that contributes to the development and maintenance of AF. 38 In addition, ER stress-induced apoptosis is initiated via the activation of NF-κB. 34 Our data demonstrate a significant attenuation in the ER stress proteins with TPPU treatment. The in vitro data also demonstrate a decrease in the activation of NF-κB with TPPU treatment. Taken together, our data suggest that treatment with TPPU decreases ER stress at least, in part, through the inhibition of NF-κB activation.
Atrial Structural Remodeling and AF
AF-induced structural remodeling is a gradual process that intensifies progressively. Excessive oxidative stress has been associated with AF leading to atrial structural remodeling, including atrial myocyte hypertrophy and fibrosis. 27, 28 Experimental animal models and clinical studies have implicated multifactorial processes including atrial dilatation, cellular hypertrophy, apoptosis, ER stress, fibrosis, and oxidative stress as contributing to structural remodeling. 27, 30 Increased fibrosis initiated by profibrotic cytokines such as TGF-β1 has been observed in patients with AF. 1, 4, 21 Atrial fibrosis has been shown to involve a complex interplay of profibrotic molecules, including ANG II and its downstream mediators, the multifunctional MAPKs, and TGF-β. 13, 24, 25 Upregulated TGF-β in cardiac fibroblasts induces cardiac fibrosis by activating Smad transcription factors, which activate the promoters of collagen I and III genes. 24, 25 TGF-β also promotes persistent perivascular and interstitial fibrosis by suppressing the activity of matrix metalloproteinases and protease inhibitors. 13, 25 Atrial myocyte hypertrophy further increases ROS production in the atrial myocytes resulting in the activation of programmed cell death and apoptosis. Increased ROS production in cardiomyocytes causes the activation of members of the MAPK pathway, ERK1/2 and JNKs, both of which have been implicated in cardiac hypertrophy. 39 Similarly, members of the pleiotropic TGF-β superfamily have been shown to promote myocardial hypertrophy. 25, 26 Here, we demonstrate an increase in both atrial fibrosis and atrial myocyte hypertrophy in the chronic pressure-overload model, which is significantly mitigated by treatment with sEHIs. Treatment with sEHI significantly decreases the activation of ERK1/2 and Smad2/3 in atrial fibroblasts and myocytes. Inhibition of sEH attenuates ROS in atrial myocytes and fibroblasts by preventing the activation of the MAPK pathway, ERK1/2 and JNK. Moreover, sEHI decreases ER stress consistent with previous findings of the reduction of ER stress response in various disease models by sEH inhibition. 32, 33 Finally, direct effects of sEHI on atrial myocytes and fibroblasts are further substantiated using in vitro model of hiPSCfibroblasts and hiPSC-ACMs.
Atrial Electric Remodeling and AF
Electric remodeling is induced by rapid atrial rates, which develops immediately after AF and contributes to the stability of a longer lasting form of AF. Abnormalities in electric impulse formation or impulse conduction can initiate and maintain AF. Excessive prolongation of APD causes Ca 2+ currents to recover from inactivation, leading to early after depolarization and maintenance of AF. 40 Our study demonstrates a slowing of activation, a prolonged APD in LA, and importantly an increased dispersion of APD and effective refractory period, a known proarrhythmic factor. At the cellular basis, electric remodeling involves changes to the ion channels governing the AP characteristics. Downregulation of I to in atrial cells can significantly alter AP shape and duration contributing to electric remodeling. A marked decrease in I to was previously documented in both animal models and patients with chronic AF. 41 The reduction in I to has been shown to be because of the decrease in the auxiliary subunit of the K + channel, thereby impairing the channel assembly via the activation of NF-κB signaling cascade. 42 SEH inhibition increases epoxyeicosatrienoic acids, which has previously been shown to regulate gene expression via the inhibition of NF-κB signaling. 9, 14 Of considerable New Treatment Paradigm for Atrial Fibrillation relevance are our findings that there is a significant upregulation of I to from single isolated atrial myocytes and an inhibition of NF-κB activation in cultured cells by treatment with sEHI. Taken together, our data support the notion that treatment with sEHI may reduce the electric remodeling in the atrial myocytes by the upregulation of outward transient K + current, possibly through the inhibition of the NF-κB activation.
Translational Implications
The emergence of hiPSC technology has created a unique tool to study the effects of various drugs in both monogenetic diseases and in diseases with multiple pathogeneses, such as AF. Advantages of using hiPSC for drug screening include the ability to circumvent the problem of maintaining primary human cardiomyocytes in culture, the ability to obtain patient-specific cell lines and the ability to avoid adverse side effects of drugs. 43 In our study, we took advantage of hiPSC-CMs as a model system to study the effects of novel sEHI on the molecular mechanisms underlying the structural and electric remodeling in AF. Indeed, hiPSC-ACMs may be used as an in vitro drug-screening tool to study atrial arrhythmias. Finally, our study provides a proofof-concept study for an upstream therapeutic target for the treatment of AF.
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